Pulmatrix, INC 8-K filings

Pulmatrix announces Q2 2026 results, highlighting progress on its merger with Eos Senolytix and efforts to out-license or monetize its clinical assets.

Pulmatrix reported first quarter 2026 financial results, highlighted by a proposed merger with Eos SENOLYTIX and a $1 million private placement.

Pulmatrix, Inc. announced the successful closing of a private placement of Series B Convertible Preferred Stock, raising approximately $1 million as a component of its planned merger with Eos SENOLYTIX, Inc.

Pulmatrix, Inc. announced a definitive merger agreement to acquire Eos SENOLYTIX, Inc., pivoting to novel mitochondrial therapies for aging-related diseases, with existing Pulmatrix shareholders retaining approximately 6% ownership of the combined entity.

Pulmatrix, Inc. announced the termination of its planned merger with Cullgen Inc. due to regulatory delays, and is now actively pursuing alternative merger opportunities.

Pulmatrix, Inc. announced its 2025 financial results and is actively pursuing licensing or monetization of its iSPERSE technology and clinical assets while the proposed merger with Cullgen awaits regulatory approval.

Pulmatrix and Cullgen have mutually waived a merger clause, allowing both companies to explore alternative transactions while awaiting China Securities Regulatory Commission approval for their proposed merger.

Pulmatrix announced its third quarter 2025 financial results, progress on its proposed merger with Cullgen, and plans to divest its iSPERSE technology and related clinical assets.

Pulmatrix announces second quarter 2025 financial results, progress on its proposed merger with Cullgen, and plans to divest its inhalation assets.

Pulmatrix, Inc. stockholders have overwhelmingly approved all proposals related to its merger with Cullgen Inc., including a reverse stock split and increased authorized shares, though the merger remains contingent on crucial approval from the China Securities Regulatory Commission.

Pulmatrix reports its Q1 2025 financial results, highlighting a divestment plan for its assets, including PUR3100, as part of the proposed merger with Cullgen, expected to close in June.

Pulmatrix, Inc. and Cullgen Inc. have amended their merger agreement to revise the transaction structure to a one-step merger.

Pulmatrix, Inc. reports the resignation of Marcum LLP as its independent registered accounting firm and the engagement of CBIZ CPAs P.C. effective April 4, 2025.

Pulmatrix reports its year-end and fourth quarter 2024 financial results, highlighting a merger agreement with Cullgen and plans to divest assets including its Phase 2-ready migraine candidate.

Pulmatrix, Inc. has amended its bylaws, effective February 11, 2025, to revise the voting standards language.

Pulmatrix, Inc. held its 2024 annual meeting of stockholders on December 18, 2024, where directors were elected and the appointment of an independent auditor was ratified.

Pulmatrix and Cullgen have announced a merger agreement to create a Nasdaq-listed company focused on targeted protein degradation technology, with three degrader programs in or about to initiate Phase 1 clinical trials.

Pulmatrix reported its third quarter 2024 financial results, highlighting cost-saving measures, the completion of the PUR1900 wind-down, and progress with its iSPERSE technology.

Pulmatrix, Inc. has announced the date for its 2024 Annual Meeting of Stockholders and established deadlines for shareholder proposals and director nominations.

Pulmatrix reported its second quarter 2024 financial results, highlighted by a cash balance of $12.4 million and an extended cash runway into Q4 2026, while also providing a corporate update on its clinical assets.

Pulmatrix, Inc. has announced the departure of CEO Teofilo Raad and the appointment of Peter Ludlum as Interim CEO, effective July 20, 2024.

Pulmatrix and MannKind have entered into a cross-licensing agreement involving Pulmatrix's iSPERSE technology and MannKind's Cricket inhalation device, with Pulmatrix transferring its R&D facility to MannKind.

Pulmatrix's inhaled migraine treatment, PUR3100, shows promising Phase 1 results with rapid drug absorption and improved tolerability compared to intravenous dihydroergotamine.

Pulmatrix announced its first quarter 2024 financial results, highlighted by a significant increase in revenue and a strategic shift in its development programs.

Pulmatrix reports its 2023 year-end financials, highlighting a cash runway extension into Q1 2026 due to cost-saving measures and a partnership amendment.

Pulmatrix Inc. has terminated its Chief Medical Officer position, transitioning to an outsourced, part-time model as part of a strategic shift.

Pulmatrix, Inc. has released a corporate presentation for distribution to the investment community and use at industry conferences.